Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

C4591031- first boost
  NCT04955626		 RCTfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
Pfizer/BioNTech Booster study
  NCT04713553		 RCTfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
-/- no results
    Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
    COVI3 OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 93 % decrease in confirmed COVID (any severity) (PE)
    • suggested 93 % decrease in symptomatic Covid-19
    McConeghy OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 97 % decrease in deaths,deaths
    • suggested 82 % decrease in hospitalization or death,hospitalization or death
    • suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
    • suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
    Kislaya OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 69 % decrease in confirmed COVID (any severity)
    Bar-On OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
    Abu-Raddad OBSfirst booster doseSpikevax (Moderna mRNA-1273 COVID-19 vaccine)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
    Abu-Raddad OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 77 % decrease in hospitalization or death
    • suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
    Arbel OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)serious
    		758118/85090 suggested
    • suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
    Barda OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		728321/728321 suggested
    • suggested 81 % decrease in deaths
    • suggested 93 % decrease in hospitalization (PE)
    Lauring OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
    		5728/5962 suggested
    • suggested 94 % decrease in hospitalization
    Patalon OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 85 % decrease in confirmed COVID (any severity)
    • suggested 92 % decrease in hospitalization
    Tenforde OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 82 % decrease in hospitalization
    Patalon OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 79 % decrease in confirmed COVID (any severity)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons